Add-on fluvoxamine and negative symptoms of schizophrenia: Analysis of data from augmentation studies in a single center

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 710-711

  Silver, Henry ^a   Bilker, Warren B ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROHEPTADINE; FLUVOXAMINE; MAPROTILINE; MOCLOBEMIDE; PLACEBO;

ADD ON THERAPY; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; SCHEDULE FOR ASSESSMENT NEGATIVE SYMPTOMS GLOBAL SCORE; SCHEDULE FOR ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SCORING SYSTEM; SIMPSON-ANGUS SCALE; TREATMENT RESPONSE;

AFFECT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FLUVOXAMINE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883803581     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182983d42     Document Type: Letter

References (19)

1. Leucht S, Heres S, Kissling W, et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269-284
2. Arndt S, Andreasen NC, Flaum M, et al. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995;52(5): 352-360
3. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992;31(7):698-704
4. Hanson E, Healey K, Wolf D, et al. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep. 2010;12(6):563-571
5. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-Analysis. Br J Psychiatry. 2010;197(3):174-179
6. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;3:CD005581
7. Riley RD, Lambert PC, Abo-Zaid G. Meta-Analysis of individual participant data: Rationale,conduct, and reporting. BMJ. 2010;340:c221-c228
8. Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study. Int Clin Psychopharmacol. 2000;15(5):257-261
9. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: Evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol. 1998;18(3):208-211
10. Silver H, Blacker M, Weller MP, et al. Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study. Biol Psychiatry. 1991;30(5):523-525
11. Silver H, Aharon N, Hausfater N, et al. The effect of augmentation with moclobemide on symptoms of schizophrenia. Int Clin Psychopharmacol. 1999;14(3):193-195
12. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study. Biol Psychiatry. 1996;40(7):671-674
13. Silver H, Susser E, Danovich L, et al. SSRI augmentation of antipsychotic alters expression of GABAA receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol. 2010;14:(5):573-584
14. Chertkow Y, Weinreb O, Youdim MB, et al. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1356-1362
15. Lammers C, Deuschle M, Weigman H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients: Clinical experience. Pharmacopsychiatry 1999;32:76-77
16. Danovich L, Weinreb O, Youdim MB, et al. Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. Psychopharmacology (Berl). 2012;220(4):763-770
17. Danovich L, Weinreb O, Youdim MB, et al. The involvement of GABAA receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-Antipsychotic treatment. Int J Neuropsychopharmacol. 2010;25:1-13
18. Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117-119
19. Chertkow Y, Weinreb O, Youdim MB, et al. Molecular mechanisms underlying synergistic effects of SSRI-Antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J Neural Transm. 2009;116(11):1529-1541